π₯π BizChicken ππ₯
Companies Similar to Atea Pharmaceuticals, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Athira Pharma, Inc.
ATH-1017
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, with its lead product, ATH-1017, in clinical trials for Alzheimer's and Parkinson's diseases.
Symbol: ATHA
Recent Price: $0.55
Industry: Biotechnology
CEO: Dr. Mark J. Litton M.B.A., Ph.D.
Sector: Healthcare
Employees: 65
Address: 18706 North Creek Parkway, Bothell, WA 98011
Phone: 425 620 8501
Last updated: 2024-12-31
Anixa Biosciences, Inc.
Chimeric Endocrine Receptor T-cell Technology, Anti-Viral Drug Candidates, Vaccines
Anixa Biosciences, Inc. is a biotechnology company focused on developing therapies and vaccines for oncology and infectious diseases, including novel CAR-T technologies for ovarian cancer and vaccines for breast and ovarian cancer.
Symbol: ANIX
Recent Price: $2.50
Industry: Biotechnology
CEO: Dr. Amit Kumar Ph.D.
Sector: Healthcare
Employees: 4
Address: 3150 Almaden Expressway, San Jose, CA 95118
Phone: 408 708 9808
Last updated: 2024-12-31
BioAtla, Inc.
BA3011
Bio Atla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Their lead product candidate is BA3011, targeting various cancers.
Symbol: BCAB
Recent Price: $0.59
Industry: Biotechnology
CEO: Dr. Jay M. Short Ph.D.
Sector: Healthcare
Employees: 65
Address: 11085 Torreyana Road, San Diego, CA 92121
Phone: 858 558 0708
Last updated: 2024-12-31
Applied Therapeutics, Inc.
AT-007
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.
About | Leadership | Leadership | Leadership | Leadership | Vision/Values | Culture | DEI | Contact | Contact | Careers | Careers | About | About | About
Symbol: APLT
Recent Price: $0.81
Industry: Biotechnology
CEO: Dr. Shoshana Shendelman Ph.D.
Sector: Healthcare
Employees: 31
Address: 545 Fifth Avenue, New York, NY 10017
Phone: 212 220 9226
Leadership
- Shoshana Shendelman, Chair, Board of Directors
- Riccardo Perfetti, Chief Medical Officer
- Les Funtleyder,
- Dale Hooks, Chief Commercial Officer
- Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
- Joel Marcus,
- Jay Skyler,
- Stacy Kanter,
- Teena Lerner,
- Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
- Roy Freeman M.D.,
- Roxana Mehran M.D.,
- Lawrence Steinman M.D.,
- Gregg Stone M.D.,
- Donald d'Amico M.D.,
- Donald Landry, Chair, Scientific Advisory Board
- Roy Freeman,
- Roxana Mehran,
- Lawrence Steinman,
- Gregg Stone,
- Donald d'Amico,
Last updated: 2024-12-31
Atea Pharmaceuticals, Inc.
AT-527
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics for viral infections, with a lead product candidate AT-527 for COVID-19 treatment.
Symbol: AVIR
Recent Price: $3.33
Industry: Biotechnology
CEO: Dr. Jean-Pierre Sommadossi Ph.D.
Sector: Healthcare
Employees: 75
Address: 125 Summer Street, Boston, MA 02110
Phone: 857 284 8891
Leadership
- Jean-Pierre Sommadossi, PhD, FOUNDER, CHAIRMAN & CEO
- Nancy Agrawal, PhD, Executive VP, Preclinical Development
- Jonae Barnes, Senior VP, Investor Relations & Corporate Communications
- Bruce Belanger, PhD, Senior VP, Biostatistics
- Andrea Corcoran, CFO & Executive VP, Legal
- Adam DeZure, MD, VP, Clinical Development
- James MB Evans, PhD, VP, CMC Manufacturing
- Wayne Foster, EXECUTIVE VP, Chief Accounting Officer
- Kerry Gagnon, VP, Head of Quality
- Steven Good, EXECUTIVE VP, PRECLINICAL SCIENCE
- Janet Hammond, MD, PhD, CHIEF DEVELOPMENT OFFICER
- Arantxa Horga, MD, Chief Medical Officer
- Qi Huang, Senior VP, Virology
- Laura Ishak, Senior VP, Clinical Operations
- Ariyapadi Krishnaraj, VP, Marketing
- Adel Moussa, PhD, EXECUTIVE VP, CHEMISTRY
- Shari Noble, VP, Deputy General Counsel
- Keith Pietropaolo, Executive VP, Clinical Sciences and Project Management
- Brian Rowe, VP, Business Development
- Marc Van Hulle, VP, Finance
- John Vavricka, CHIEF COMMERCIAL OFFICER
- Alex Vo, PhD, VP, DMPK
- Jayanthi Wolf, PhD, Executive VP, Regulatory Affairs
- Xiao-Jian Zhou, PhD, EXECUTIVE VP, EARLY STAGE DEVELOPMENT
Last updated: 2024-12-31
Vera Therapeutics, Inc.
atacicept
Vera Therapeutics, Inc. is a clinical stage biotechnology company focusing on developing and commercializing treatments for serious immunological diseases, including atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia infections.
Careers | About | About | About | About | Contact | Careers | Careers | Jobs | About | About | Jobs | Careers
Symbol: VERA
Recent Price: $42.06
Industry: Biotechnology
CEO: Dr. Marshall W. Fordyce M.D.
Sector: Healthcare
Employees: 72
Address: 8000 Marina Boulevard, Brisbane, CA 94005
Phone: 650 770 0077
Last updated: 2024-12-31
Apogee Therapeutics, Inc.
APG777, APG808, APG990, APG222
Apogee Therapeutics, Inc. is a biotechnology company developing biologics for the treatment of atopic dermatitis, COPD, and related inflammatory and immunology conditions. Founded in 2022 and based in Waltham, Massachusetts.
Symbol: APGE
Recent Price: $44.64
Industry: Biotechnology
CEO: Dr. Michael Thomas Henderson M.D.
Sector: Healthcare
Employees: 91
Address: 221 Crescent Street, Waltham, MA 02453
Phone: 650-394-5230
Last updated: 2024-12-31
Aprea Therapeutics, Inc.
ATRN-119
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.
Symbol: APRE
Recent Price: $3.48
Industry: Biotechnology
CEO: Dr. Oren Gilad Ph.D.
Sector: Healthcare
Employees: 7
Address: 535 Boylston St., Boston, MA 02116
Phone: 617-463-9385
Last updated: 2024-12-31
Atossa Therapeutics, Inc.
Endoxifen
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for oncology and infectious diseases with key programs in breast cancer and COVID-19 treatment.
Symbol: ATOS
Recent Price: $0.97
Industry: Biotechnology
CEO: Dr. Steven C. Quay FCAP, M.D., Ph.D.
Sector: Healthcare
Employees: 12
Address: 107 Spring Street, Seattle, WA 98104
Phone: 206 588 0256
Last updated: 2024-12-31
Atara Biotherapeutics, Inc.
T-cell immunotherapy treatments
Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.
About | About | About | Contact | About | Careers | Careers | About | Careers | Careers | About | About
Symbol: ATRA
Recent Price: $13.28
Industry: Biotechnology
CEO: Dr. Anhco Nguyen Ph.D.
Sector: Healthcare
Employees: 165
Address: 611 Gateway Boulevard, South San Francisco, CA 94080
Phone: 650 278 8930
Last updated: 2024-12-31
Astria Therapeutics, Inc.
STAR-0215
Astria Therapeutics, Inc., is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic and immunological diseases in the United States. Its lead product candidate, STAR-0215, is targeting hereditary angioedema.
Symbol: ATXS
Recent Price: $8.88
Industry: Biotechnology
CEO: Ms. Jill C. Milne Ph.D.
Sector: Healthcare
Employees: 59
Address: 100 High Street, Boston, MA 02110
Phone: 617 349 1971
Last updated: 2024-12-31
Aerovate Therapeutics, Inc.
AV-101
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for rare cardiopulmonary diseases, with a lead product AV-101 for pulmonary arterial hypertension.
Symbol: AVTE
Recent Price: $2.66
Industry: Biotechnology
CEO: Mr. Timothy P. Noyes M.B.A.
Sector: Healthcare
Employees: 51
Address: 930 Winter Street, Waltham, MA 02116
Phone: 617 443 2400
Last updated: 2024-12-31
Cocrystal Pharma, Inc.
CC-31244, CC-42344
Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral drugs for tackling serious and chronic viral diseases such as hepatitis C, influenza, coronavirus, and norovirus.
About | About | About | Leadership | Directors | About | About | Contact | Careers | About | About
Symbol: COCP
Recent Price: $3.25
Industry: Biotechnology
CEO: Dr. Sam Lee Ph.D.
Sector: Healthcare
Employees: 12
Address: 19805 North Creek Parkway, Bothell, WA 98011
Phone: 786 459 1831
Leadership
- Sam Lee, Ph.D., Co-Chief Executive Officer and President
- James J. Martin, Co-Chief Executive Officer and Chief Financial Officer
- Roger Kornberg, Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
- Steve Rubin, Vice Chairman
- Phillip Frost, Director
- Fred Hassan, Director
- Anthony Japour, President, CEO and Director
- Richard C. Pfenniger, Jr., Director
Last updated: 2024-12-31
Indaptus Therapeutics, Inc.
Decoy20
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.
Symbol: INDP
Recent Price: $0.87
Industry: Biotechnology
CEO: Mr. Jeffrey A. Meckler
Sector: Healthcare
Employees: 7
Address: 3 Columbus Circle, New York, NY 10019
Phone: 347 480 9760
Last updated: 2024-12-31
iTeos Therapeutics, Inc.
inupadenant, EOS-448
Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of immuno-oncology therapeutics. Their product pipeline includes inupadenant and EOS-448, which are in various phases of clinical trials.
About | Leadership | Directors | About | About | About | About | Contact | Careers | About | About | About | About | About | About
Symbol: ITOS
Recent Price: $7.29
Industry: Biotechnology
CEO: Dr. Michel Detheux Ph.D.
Sector: Healthcare
Employees: 157
Address: 321 Arsenal Street, Cambridge, MA 02472-5710
Phone: 339 217 0161
Leadership
- Michel DETHEUX, President, Chief Executive Officer
- Matt CALL, Chief Operating Officer
- Matthew GALL, Chief Financial Officer
- Yvonne MCGRATH, Chief Scientific Officer
- David Feltquate, Chief Medical Officer
- Philippe BRANTEGEM, Executive Vice President of Human Resources
- Adi OSOVSKY, Executive Vice President of Legal
- David HALLAL, Chair of the Board
- Aaron DAVIS,
- Jill DESIMONE,
- David LEE,
- Tim VAN HAUWERMEIREN,
- Tony HO,
- Robert IANNONE,
- Ann RHOADS,
Last updated: 2024-12-31
Vir Biotechnology, Inc.
Sotrovimab (VIR-7832), VIR-2218, VIR-3434, VIR-2482, VIR-1111
Vir Biotechnology, Inc. is a commercial-stage immunology company developing therapeutic products to treat and prevent serious infectious diseases, including COVID-19, hepatitis B, influenza A, and HIV.
Vision/Values | About | Leadership | About | Contact | Contact | Careers | Jobs | About | About
Symbol: VIR
Recent Price: $7.33
Industry: Biotechnology
CEO: Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Sector: Healthcare
Employees: 587
Address: 499 Illinois Street, San Francisco, CA 94158
Phone: 415 906 4324
Leadership
- Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer and Director
- Jeff Calcagno, M.D., Executive Vice President and Chief Business Officer
- Vanina de Verneuil, J.D., Executive Vice President, General Counsel and Corporate Secretary
- Mika Kakefuda Derynck, M.D., Executive Vice President, Therapeutic Area Head Oncology
- Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer
- Jenny Gumm, Ed.D., MBA, Executive Vice President, Chief Human Resources Officer
- Aine Hanly, Ph.D., Executive Vice President and Chief Technology Officer
- Jason OβByrne, MBA, Executive Vice President and Chief Financial Officer
- Jennifer Eileen Towne, Ph.D., Executive Vice President and Chief Scientific Officer
- Arran Attridge, Senior Vice President Corporate Communications
- Antonio Lanzavecchia, M.D., Senior Vice President and Senior Research Fellow
- Amalio Telenti, M.D, Ph.D., Executive Vice President and Senior Research Fellow
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Arbutus Biopharma Corporation
AB-729, AB-836, AB-161, AB-101
Arbutus Biopharma Corporation is a biopharmaceutical company that develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses. The company's HBV product pipeline includes RNA interference products and oral capsid inhibitors, and it is involved in strategic alliances for research and development.
About | Leadership | Directors | Contact | Contact | Culture | Jobs | Culture | About | About
Symbol: ABUS
Recent Price: $3.20
Industry: Biotechnology
CEO: Mr. Michael J. McElhaugh
Sector: Healthcare
Employees: 73
Address: 701 Veterans Circle, Warminster, PA 18974
Phone: 267 469 0914
Leadership
- Michael J. McElhaugh, Interim President and Chief Executive Officer and Director
- Michael J. Sofia PhD, Chief Scientific Officer
- Karen Sims, MD, PhD, Chief Medical Officer
- David C. Hastings, Chief Financial Officer
- Christopher Naftzger, General Counsel and Chief Compliance Officer
- Lisa Caperelli, Vice President, Investor Relations
- Shannon Briscoe, SPHR, SHRM-SCP, Vice President, Human Resources
- Frank Torti, MD, Chairman
- Daniel Burgess, Independent Director
- Richard C. Henriques, Independent Director
- Keith Manchester, MD, Independent Director
- James Meyers, Independent Director
- Melissa V. Rewolinski, PhD, Independent Director
Last updated: 2024-12-31
Enanta Pharmaceuticals, Inc.
N/A
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases, with targets including respiratory syncytial virus, SARS-Co V-2, human metapneumovirus, and hepatitis B virus.
About | Leadership | Directors | Contact | Careers | Careers | Culture | About | About | About
Symbol: ENTA
Recent Price: $5.85
Industry: Biotechnology
CEO: Dr. Jay R. Luly Ph.D.
Sector: Healthcare
Employees: 145
Address: 500 Arsenal Street, Watertown, MA 02472
Phone: 617 607 0800
Leadership
- Jay R. Luly, Ph.D., President, Chief Executive Officer and Director
- Tara L. Kieffer, Ph.D., Chief Product Strategy Officer
- Matthew P. Kowalsky, J.D., Chief Legal Officer
- Brendan Luu, Chief Business Officer
- Paul J. Mellett, Chief Financial and Administrative Officer
- Yat Sun Or, Ph.D., Chief Scientific Officer
- Scott T. Rottinghaus, M.D., Chief Medical Officer
- Bruce L.A. Carter, Ph.D., Chairman of the Board
- Mark G. Foletta, Board Member
- Yujiro S. Hata, Board Member
- Kristine Peterson, Board Member
- Lesley Russell, MBChB, MRCPb, Board Member
- Terry Vance, Board Member
Last updated: 2024-12-31
Viracta Therapeutics, Inc.
Nana-val
Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for the treatment of virus-associated malignancies, with a lead product candidate Nana-val in clinical trials for Epstein-Barr virus-positive lymphoma and other related conditions.
Leadership | Contact | Careers | About | Careers | About | About | About | About | About | About
Symbol: VIRX
Recent Price: $0.16
Industry: Biotechnology
CEO: Mr. Mark Andrew Rothera
Sector: Healthcare
Employees: 40
Address: 2533 South Coast Highway 101, Cardiff-by-the-Sea, CA 92007
Phone: 858 400 8470
Leadership
- Mark Rothera, President and Chief Executive Officer
- Darrel P. Cohen, M.D., Ph.D., Chief Medical Officer
- Ayman Elguindy, Ph.D., Chief Scientific Officer
- Michael Faerm, MBA, Chief Financial Officer
- Cheryl Madsen, Senior Vice President, Regulatory
- Patric Nelson, MBA, Senior Vice President, Business Development & Corporate Strategy
- Biljana Nadjsombati, Pharm.D., Senior Vice President, Pharmaceutical Development
- Violetta Akopian, Ph.D., Vice President, Quality Assurance
- Ruby Cheema, Vice President, Portfolio and Program Management
- Mark A. McCamish, M.D., Ph.D., Strategic Advisor
- Roger J. Pomerantz, M.D., Chairman of the Board
- Jane F. Barlow, M.D., MPH, MBA, Director
- Flavia Borellini, Ph.D., Director
- Jane Chung, R.Ph., Director
- Thomas E. Darcy, CPA, Director
- Sam Murphy, Ph.D., Director
- Ivor Royston, M.D., Director
- Stephen Rubino, Ph.D., MBA, Director
- Barry J. Simon, M.D., Director
- Douglas V. Faller, M.D., Ph.D., Scientific Founder and Chairman, Scientific Advisory Board
- Robert Baiocchi, M.D., Ph.D., Scientific Advisor
- Gavin Giovannoni, MBBCh, Ph.D., FCP (Neurol., SA), FRCP, FRCPath, Scientific Advisor
- Carl June, M.D., Scientific Advisor
- Shannon Kenney, M.D., Scientific Advisor
- Ronald Levy, M.D., Scientific Advisor
- Pierluigi Porcu, M.D., Scientific Advisor
- Daniel D. Von Hoff, M.D., F.A.C.P. FASCO, FAACR, Scientific Advisor
- Lawrence Young, Ph.D., Scientific Advisor
Last updated: 2024-12-31